Skip to Main Content

Paper Details

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Cancer Cell
150
2017
Abemaciclib, CCND1 3'UTR, CDK4, CDK4/6, CDK6, D-cyclin, D-cyclin-dependent Rb kinases, D-type Cyclins, Rb, Rb-positive cancers, abemaciclib, breast cancer, cancer, cancers, endometrial cancer, lymphomas, retinoblastoma, tumor, tumor types

Datasets

Release 1.2